Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes
Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry
Pedro A. Lemos, MD*,
Chi-hang Lee, MBBS, MRCP*,
Muzaffer Degertekin, MD*,
Francesco Saia, MD*,
Kengo Tanabe, MD*,
Chourmouzios A. Arampatzis, MD*,
Angela Hoye, MB ChB, MRCP*,
Marco van Duuren*,
Giorgios Sianos, MD*,
Pieter C. Smits, MD, PhD*,
Pim de Feyter, MD, PhD*,
Willem J. van der Giessen, MD, PhD*,
Ron T. van Domburg, PhD* and
Patrick W. Serruys, MD, PhD, FESC, FACC*,*
* Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands
View larger version (18K):
[in a new window]
|
Figure 1 Cumulative major adverse cardiac events (MACE) rate (death, nonfatal myocardial infarction, or re-intervention) during the first month for control patients (bare stent) and patients treated with sirolimus-eluting stents (SES). Note that >50% of events occurred during the first week in both groups.
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Multivariate independent predictors of 30-day major adverse cardiac events (MACE) rate (death, nonfatal myocardial infarction, and re-intervention) derived from the final logistic regression model. The odds ratios (OR) are shown on logarithmic scale together with their 95% confidence interval (CI).
|
|
View larger version (46K):
[in a new window]
|
Figure 3 Comparison of the strength (chi-square values) for the prediction of 30-day major adverse cardiac events (MACE) rate (death, nonfatal myocardial infarction, and re-intervention) of multivariate models. Model 1 is the final model selected in the logistic regression analysis and included the variables displayed in Figure 2. The forced inclusion of sirolimus-eluting stent (SES) utilization (Model 2) did not enhance the predictive strength of the model, as reflected by the negligible change in the chi-square values.
|
|
|
